About Strides Pharma Science Limited
Data last updated: 06 March 2026
Strides Pharma Science Limited is a public limited company based in Thane, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 28 June 1990, the company has been in operation for over 36 years.
Registered with ROC Mumbai under CIN L24230MH1990PLC057062. Listed on BSE: 532531 and NSE: STAR.
Capital: an authorised share capital of ₹218.37 Cr and a paid-up capital of ₹92.17 Cr. Formerly known as Strides Pharma Sciences Limited and Strides Shasun Limited. It is led by directors including Homi Rustam Khusrokhan and Badree Komandur.
Last AGM: 07 August 2025. Financial statements filed for year ended 31 March 2025. Office: Sector 30, Thane, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹4,624.06 Cr, a growth of 18% compared to the previous year.
The company has a workforce of approximately 2,152 employees as per the latest available data. Its group structure includes 3 subsidiaries.
The company is associated with 1 brand - Strides Pharma Science. As per MCA filings, the company has open charges of ₹1,880.26 Cr and satisfied charges of ₹11,468 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website strides.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressCyber One Unit No. 902 Sector 30A, Plot No – 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Strides Pharma Science Limited
Strides Pharma Science Limited has undergone 7 name changes throughout its history. The current legal name is Strides Pharma Science Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Strides Pharma Science Limited | Current |
| Strides Pharma Sciences Limited | Previous |
| Strides Shasun Limited | Previous |
| Strides Arcolab Limited | Previous |
| Strides Pharma Limited | Previous |
| Strides Pharmaceuticals Limited | Previous |
| Strides Pharmaceuticals Private Limited | Previous |
| Strides Limited | Previous |
Associated Brands with Strides Pharma Science Limited
Strides Pharma Science Limited operates one associated brand: Strides Pharma Science. These brands represent Strides Pharma Science Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Generic, semi-solid, and liquid dosage forms are manufactured. | strides.com |
Business Activity of Strides Pharma Science Limited
Strides Pharma Science Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Strides Pharma Science Limited
Strides Pharma Science Limited is audited by BSR & Co., LLP (ICAI peer reviewed, certificate valid till 2027-03-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| BSR & Co., LLP (ICAI peer reviewed, certificate valid till 2027-03-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Strides Pharma Science Limited
Strides Pharma Science Limited is currently managed by 10 directors, with 29 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Homi Rustam Khusrokhan
Also directs:
Neuland Laboratories Ltd., The Anglo Scottish Education Society
|
Director | 18 May 2017 | 9 Years 1 Months | Current |
| Badree Komandur | Managing Director | 18 May 2017 | 9 Years 1 Months | Current |
|
Subir Chakraborty
Also directs:
Ifb Industries Ltd
|
Director | 01 Jun 2024 | 2 Years 1 Months | Current |
|
Ameet Pratapsinh Hariani
Also directs:
Adf Foods Limited, Mahindra Lifespace Developers Limited, Mahindra Logistics Limited and 5 more
|
Director | 01 Feb 2024 | 2 Years 5 Months | Current |
| Aditya Arun Kumar | Whole-Time Director | 01 Jun 2024 | 2 Years 1 Months | Current |
|
Mukta Malik Arora
Also directs:
Astellas Pharma Capability Centre India Private Limited
|
Director | 01 Feb 2025 | 1 Years 5 Months | Current |
Financials of Strides Pharma Science Limited FY 2026 filings available
Strides Pharma Science Limited reported revenue of ₹4,858.68 Cr (up 6.43% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹4,858.68 Cr | ₹4,565.34 Cr | ₹4,051.12 Cr | ₹3,688.39 Cr | ₹3,070.25 Cr | ₹3,315.87 Cr | ₹2,751.97 Cr |
| Other Income | ₹150.71 Cr | ₹58.72 Cr | ₹39.7 Cr | ₹90.33 Cr | ₹131.99 Cr | ₹51.43 Cr | ₹53.11 Cr |
| Total Income | ₹5,009.4 Cr | ₹4,624.06 Cr | ₹4,090.83 Cr | ₹3,778.72 Cr | ₹3,202.24 Cr | ₹3,367.3 Cr | ₹2,805.08 Cr |
| Cost of Materials Consumed | ₹1,558.92 Cr | ₹1,475.89 Cr | ₹1,341.11 Cr | ₹1,441.68 Cr | ₹1,090.93 Cr | ₹1,390.42 Cr | ₹1,020.35 Cr |
| Purchases of Stock-in-Trade | ₹361.54 Cr | ₹688.08 Cr | ₹283.45 Cr | ₹187.87 Cr | ₹316.11 Cr | ₹296.08 Cr | ₹146.94 Cr |
| Changes in Inventories | ₹38.28 Cr | -₹184.01 Cr | ₹15.94 Cr | -₹2.67 Cr | ₹95.28 Cr | -₹353.71 Cr | -₹44.81 Cr |
| Employee Benefit Expense | ₹928.96 Cr | ₹862.76 Cr | ₹751.13 Cr | ₹732.02 Cr | ₹646.91 Cr | ₹550.15 Cr | ₹442.56 Cr |
| Finance Costs | ₹178.55 Cr | ₹248.85 Cr | ₹314.45 Cr | ₹261.14 Cr | ₹176.74 Cr | ₹150.07 Cr | ₹155.72 Cr |
| Depreciation & Amortisation | ₹202.4 Cr | ₹192.26 Cr | ₹220.68 Cr | ₹243.25 Cr | ₹233.01 Cr | ₹206.29 Cr | ₹173.7 Cr |
| Other Expenses | ₹1,045.7 Cr | ₹919.8 Cr | ₹916.23 Cr | ₹899.3 Cr | ₹941.13 Cr | ₹798.1 Cr | ₹671.03 Cr |
| Total Expenses | ₹4,314.34 Cr | ₹4,203.63 Cr | ₹3,842.99 Cr | ₹3,762.6 Cr | ₹3,500.11 Cr | ₹3,037.39 Cr | ₹2,565.49 Cr |
| Profit Before Exceptional Items & Tax | ₹695.06 Cr | ₹420.42 Cr | ₹247.84 Cr | ₹16.12 Cr | -₹297.88 Cr | ₹329.91 Cr | ₹239.59 Cr |
| Exceptional Items | -₹26.84 Cr | ₹64.66 Cr | -₹189.05 Cr | -₹17.03 Cr | -₹243.83 Cr | ₹43.35 Cr | -₹77.68 Cr |
| Profit Before Tax | ₹668.22 Cr | ₹485.08 Cr | ₹58.79 Cr | -₹91.7 Lakh | -₹541.7 Cr | ₹373.26 Cr | ₹161.91 Cr |
| Total Tax Expense | ₹94.17 Cr | ₹77.52 Cr | ₹31.59 Cr | -₹55.3 Cr | -₹178.26 Cr | ₹31.65 Cr | ₹11.33 Cr |
| Net Profit | ₹574.52 Cr | ₹3,597.51 Cr | -₹94.31 Cr | -₹212.33 Cr | -₹474.25 Cr | ₹257.73 Cr | ₹30.58 Cr |
| attributable to Owners | ₹556.19 Cr | ₹3,593.46 Cr | -₹70.61 Cr | -₹202.64 Cr | -₹460.21 Cr | ₹268.44 Cr | ₹36.38 Cr |
| attributable to NCI | ₹18.33 Cr | ₹4.06 Cr | -₹23.7 Cr | -₹9.7 Cr | -₹14.04 Cr | -₹10.71 Cr | -₹5.8 Cr |
| Other Comprehensive Income | ₹44.02 Cr | ₹149.81 Cr | -₹54.7 Cr | ₹7.92 Cr | ₹49 Cr | ₹16.56 Cr | ₹37.07 Cr |
| Total Comprehensive Income | ₹618.54 Cr | ₹3,747.32 Cr | -₹149.02 Cr | -₹204.41 Cr | -₹425.25 Cr | ₹274.28 Cr | ₹67.65 Cr |
| EBITDA (computed) | ₹1,076.01 Cr | ₹861.53 Cr | ₹782.97 Cr | ₹520.51 Cr | ₹111.88 Cr | ₹686.26 Cr | ₹569.01 Cr |
| Basic EPS | ₹60.34 | ₹44.05 | ₹-13.72 | ₹-24.56 | ₹-51.28 | ₹28.40 | ₹5.68 |
| Diluted EPS | ₹60.34 | ₹44.05 | ₹-13.72 | ₹-24.56 | ₹-51.28 | ₹28.37 | ₹5.68 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹6,927.23 Cr | ₹6,048.73 Cr | ₹5,839.76 Cr | ₹6,638.42 Cr |
| Non-current Assets | ₹3,313.89 Cr | ₹2,949.81 Cr | ₹2,870.76 Cr | ₹3,395.06 Cr |
| Current Assets | ₹3,612.79 Cr | ₹3,098.91 Cr | ₹2,969 Cr | ₹3,135.25 Cr |
| Property, Plant & Equipment | ₹992.43 Cr | ₹880.69 Cr | ₹878.67 Cr | ₹1,324.29 Cr |
| Inventories | ₹1,634.79 Cr | ₹1,277.57 Cr | ₹1,126.24 Cr | ₹1,146.51 Cr |
| Trade Receivables | ₹1,288.96 Cr | ₹1,202.94 Cr | ₹1,141.87 Cr | ₹1,299.4 Cr |
| Cash & Equivalents | ₹188.7 Cr | ₹112.56 Cr | ₹161.02 Cr | ₹303.5 Cr |
| Equity (Net Worth) | ₹3,149.34 Cr | ₹2,586.46 Cr | ₹2,071.71 Cr | ₹2,172.88 Cr |
| Equity Share Capital | ₹92.17 Cr | ₹92.16 Cr | ₹91.9 Cr | ₹90.3 Cr |
| Borrowings (Non-current) | ₹552.32 Cr | ₹571.24 Cr | ₹671.5 Cr | ₹1,139.79 Cr |
| Borrowings (Current) | ₹1,116.37 Cr | ₹1,224.37 Cr | ₹1,743.03 Cr | ₹1,634.67 Cr |
| Total Debt (computed) | ₹1,668.69 Cr | ₹1,795.61 Cr | ₹2,414.53 Cr | ₹2,774.46 Cr |
| Current Liabilities | ₹2,895.49 Cr | ₹2,591.52 Cr | ₹2,879.26 Cr | ₹2,990.2 Cr |
| Total Liabilities | ₹3,777.9 Cr | ₹3,462.26 Cr | ₹3,768.05 Cr | ₹4,465.54 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹702.52 Cr | ₹684.37 Cr | ₹701.07 Cr | ₹44.41 Cr | -₹257.82 Cr |
| Investing Cash Flow | -₹173.04 Cr | -₹89.69 Cr | -₹150.25 Cr | ₹302.47 Cr | -₹118.73 Cr |
| Financing Cash Flow | -₹453.41 Cr | -₹642.58 Cr | -₹693.32 Cr | -₹213.92 Cr | ₹421.32 Cr |
| Capital Expenditure | ₹422.94 Cr | ₹242.5 Cr | ₹118.15 Cr | ₹94.94 Cr | ₹143.38 Cr |
| Free Cash Flow (computed) | ₹279.58 Cr | ₹441.88 Cr | ₹582.91 Cr | -₹50.53 Cr | -₹401.2 Cr |
| Dividends Paid | ₹36.87 Cr | ₹22.99 Cr | ₹13.52 Cr | ₹0 | ₹22.43 Cr |
| Net Change in Cash | ₹76.13 Cr | -₹48.43 Cr | -₹142.48 Cr | ₹132.77 Cr | ₹44.9 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,323.47 Cr | ₹1,194.65 Cr | ₹1,220.83 Cr | ₹1,119.74 Cr | ₹1,190.39 Cr | ₹1,153.67 Cr | ₹1,201.11 Cr | ₹1,087.51 Cr | ₹1,084.04 Cr | ₹1,037.67 Cr | ₹999.43 Cr | ₹929.99 Cr |
| Other Income | ₹8.13 Cr | ₹106.86 Cr | ₹27.14 Cr | ₹8.58 Cr | ₹11.98 Cr | ₹5.62 Cr | ₹28.41 Cr | ₹12.72 Cr | -₹13.55 Cr | ₹8.75 Cr | ₹35.85 Cr | ₹8.65 Cr |
| Total Income | ₹1,331.6 Cr | ₹1,301.51 Cr | ₹1,247.97 Cr | ₹1,128.32 Cr | ₹1,202.37 Cr | ₹1,159.28 Cr | ₹1,229.52 Cr | ₹1,100.22 Cr | ₹1,070.49 Cr | ₹1,046.42 Cr | ₹1,035.28 Cr | ₹938.64 Cr |
| Cost of Materials Consumed | ₹408.88 Cr | ₹459.71 Cr | ₹429.76 Cr | ₹260.58 Cr | ₹269.73 Cr | ₹476.58 Cr | ₹448.85 Cr | ₹364.21 Cr | ₹353.84 Cr | ₹375.13 Cr | ₹342.3 Cr | ₹269.85 Cr |
| Purchases of Stock-in-Trade | ₹127.45 Cr | ₹71.38 Cr | ₹41.8 Cr | ₹120.91 Cr | ₹231.6 Cr | ₹133.77 Cr | ₹55.33 Cr | ₹79.44 Cr | ₹112.64 Cr | ₹50.66 Cr | ₹63.64 Cr | ₹56.5 Cr |
| Changes in Inventories | -₹7.7 Lakh | -₹68.14 Cr | ₹43.71 Cr | ₹62.79 Cr | -₹2.36 Cr | -₹130.23 Cr | -₹6.26 Cr | -₹23.21 Cr | -₹50.25 Cr | -₹4.55 Cr | ₹12.15 Cr | ₹58.6 Cr |
| Employee Benefit Expense | ₹247.11 Cr | ₹229.54 Cr | ₹226.78 Cr | ₹225.52 Cr | ₹222.86 Cr | ₹215.64 Cr | ₹219.41 Cr | ₹212.17 Cr | ₹199.17 Cr | ₹184.49 Cr | ₹199.93 Cr | ₹167.53 Cr |
| Finance Costs | ₹41.58 Cr | ₹43.38 Cr | ₹46.13 Cr | ₹47.46 Cr | ₹50.32 Cr | ₹52.18 Cr | ₹82.15 Cr | ₹80.39 Cr | ₹80.16 Cr | ₹79.28 Cr | ₹78.59 Cr | ₹76.42 Cr |
| Depreciation & Amortisation | ₹53.25 Cr | ₹50.62 Cr | ₹49.64 Cr | ₹48.89 Cr | ₹48.86 Cr | ₹48.42 Cr | ₹50.52 Cr | ₹48.59 Cr | ₹49.76 Cr | ₹51.23 Cr | ₹60.11 Cr | ₹59.59 Cr |
| Other Expenses | ₹300.4 Cr | ₹266.22 Cr | ₹247.22 Cr | ₹231.86 Cr | ₹250.69 Cr | ₹247.59 Cr | ₹247.97 Cr | ₹237.91 Cr | ₹238.91 Cr | ₹238.12 Cr | ₹228.28 Cr | ₹210.92 Cr |
| Total Expenses | ₹1,178.59 Cr | ₹1,052.7 Cr | ₹1,085.03 Cr | ₹998.01 Cr | ₹1,071.71 Cr | ₹1,043.96 Cr | ₹1,097.98 Cr | ₹999.51 Cr | ₹984.22 Cr | ₹974.37 Cr | ₹984.99 Cr | ₹899.41 Cr |
| Profit Before Exceptional Items & Tax | ₹153.01 Cr | ₹248.81 Cr | ₹162.94 Cr | ₹130.31 Cr | ₹130.67 Cr | ₹115.32 Cr | ₹131.55 Cr | ₹100.71 Cr | ₹86.27 Cr | ₹72.05 Cr | ₹50.29 Cr | ₹39.23 Cr |
| Exceptional Items | -₹6.41 Cr | -₹3.3 Cr | -₹8.77 Cr | -₹8.37 Cr | -₹27.42 Cr | -₹2.43 Cr | -₹3.87 Cr | -₹3.74 Cr | -₹8.07 Cr | -₹10.07 Cr | -₹164.93 Cr | -₹5.98 Cr |
| Profit Before Tax | ₹146.6 Cr | ₹245.51 Cr | ₹154.17 Cr | ₹121.94 Cr | ₹103.25 Cr | ₹112.89 Cr | ₹127.67 Cr | ₹96.98 Cr | ₹78.2 Cr | ₹61.99 Cr | -₹114.64 Cr | ₹33.25 Cr |
| Total Tax Expense | ₹18.77 Cr | ₹37.35 Cr | ₹21.59 Cr | ₹16.45 Cr | ₹20.76 Cr | ₹23.81 Cr | ₹21.2 Cr | ₹16.86 Cr | ₹19.25 Cr | ₹10.1 Cr | -₹7.44 Cr | ₹9.68 Cr |
| Net Profit | ₹129.28 Cr | ₹208.12 Cr | ₹131.52 Cr | ₹105.59 Cr | ₹85.62 Cr | ₹90.04 Cr | ₹93.66 Cr | ₹68.31 Cr | ₹10.44 Cr | ₹54.06 Cr | -₹149.46 Cr | -₹9.36 Cr |
| attributable to Owners | ₹126.94 Cr | ₹202.11 Cr | ₹127.53 Cr | ₹99.61 Cr | ₹82.19 Cr | ₹87.95 Cr | ₹93.23 Cr | ₹70.2 Cr | ₹18.18 Cr | ₹49.67 Cr | -₹131.34 Cr | -₹7.11 Cr |
| attributable to NCI | ₹2.34 Cr | ₹6.02 Cr | ₹3.99 Cr | ₹5.99 Cr | ₹3.42 Cr | ₹2.09 Cr | ₹42.9 Lakh | -₹1.89 Cr | -₹7.73 Cr | ₹4.39 Cr | -₹18.11 Cr | -₹2.25 Cr |
| Other Comprehensive Income | ₹19.7 Cr | ₹9.88 Cr | -₹24.25 Cr | ₹38.69 Cr | ₹77.12 Cr | ₹72.43 Cr | ₹10.03 Cr | -₹9.85 Cr | -₹53.31 Cr | ₹6.13 Cr | -₹6.65 Cr | -₹88.3 Lakh |
| Total Comprehensive Income | ₹148.99 Cr | ₹218 Cr | ₹107.27 Cr | ₹144.28 Cr | ₹162.73 Cr | ₹162.47 Cr | ₹103.69 Cr | ₹58.46 Cr | -₹42.87 Cr | ₹60.19 Cr | -₹156.1 Cr | -₹10.24 Cr |
| EBITDA (computed) | ₹247.84 Cr | ₹342.81 Cr | ₹258.71 Cr | ₹226.66 Cr | ₹229.85 Cr | ₹215.93 Cr | ₹264.22 Cr | ₹229.7 Cr | ₹216.19 Cr | ₹202.57 Cr | ₹188.98 Cr | ₹175.24 Cr |
| Basic EPS | ₹13.77 | ₹21.93 | ₹13.84 | ₹10.81 | ₹8.92 | ₹9.56 | ₹10.14 | ₹7.64 | ₹1.97 | ₹-0.49 | ₹-14.54 | ₹-0.79 |
| Diluted EPS | ₹13.77 | ₹21.92 | ₹13.84 | ₹10.81 | ₹8.92 | ₹9.55 | ₹10.12 | ₹7.62 | ₹1.97 | ₹-0.49 | ₹-14.54 | ₹-0.79 |
| Segment · FY 2024 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Bio-pharmaceutical business | ₹0 | -₹121.94 Cr | - | - |
| Pharmaceutical business | ₹4,051.12 Cr | ₹319.44 Cr | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹2,180.14 Cr | ₹2,139.42 Cr | ₹2,153.26 Cr | ₹1,854.5 Cr | ₹1,979 Cr | ₹1,857.57 Cr | ₹1,674.15 Cr |
| Other Income | ₹123.06 Cr | ₹46.19 Cr | ₹72.31 Cr | ₹84.07 Cr | ₹123.49 Cr | ₹89 Cr | ₹100.16 Cr |
| Total Income | ₹2,303.2 Cr | ₹2,185.61 Cr | ₹2,225.56 Cr | ₹1,938.56 Cr | ₹2,102.49 Cr | ₹1,946.56 Cr | ₹1,774.31 Cr |
| Cost of Materials Consumed | ₹1,019.6 Cr | ₹1,048.11 Cr | ₹1,072.63 Cr | ₹1,020.1 Cr | ₹935.42 Cr | ₹1,050.1 Cr | ₹848.34 Cr |
| Purchases of Stock-in-Trade | ₹79.4 Cr | ₹62.63 Cr | ₹29.23 Cr | ₹24.47 Cr | ₹51.83 Cr | ₹56.31 Cr | ₹38.46 Cr |
| Changes in Inventories | ₹11.02 Cr | -₹27.2 Cr | ₹4.62 Cr | ₹21.04 Cr | ₹114.26 Cr | -₹117.53 Cr | ₹1.18 Cr |
| Employee Benefit Expense | ₹381.6 Cr | ₹377.59 Cr | ₹335.21 Cr | ₹267.01 Cr | ₹272.09 Cr | ₹272.72 Cr | ₹221.77 Cr |
| Finance Costs | ₹113.77 Cr | ₹145.91 Cr | ₹167.93 Cr | ₹138.68 Cr | ₹74.24 Cr | ₹65.34 Cr | ₹66.71 Cr |
| Depreciation & Amortisation | ₹91.24 Cr | ₹84.61 Cr | ₹84.67 Cr | ₹93.62 Cr | ₹104.37 Cr | ₹99.34 Cr | ₹91.63 Cr |
| Other Expenses | ₹403.47 Cr | ₹415.86 Cr | ₹456.3 Cr | ₹423.4 Cr | ₹528.77 Cr | ₹408.65 Cr | ₹354.36 Cr |
| Total Expenses | ₹2,100.1 Cr | ₹2,107.5 Cr | ₹2,150.58 Cr | ₹1,988.32 Cr | ₹2,080.98 Cr | ₹1,834.93 Cr | ₹1,622.45 Cr |
| Profit Before Exceptional Items & Tax | ₹203.1 Cr | ₹78.11 Cr | ₹74.99 Cr | -₹49.76 Cr | ₹21.51 Cr | ₹111.64 Cr | ₹151.86 Cr |
| Exceptional Items | ₹0 | -₹2.7 Lakh | -₹5.37 Cr | -₹15 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹203.1 Cr | ₹78.08 Cr | ₹69.62 Cr | -₹64.76 Cr | ₹21.51 Cr | ₹111.64 Cr | ₹151.86 Cr |
| Total Tax Expense | ₹19.47 Cr | ₹18.93 Cr | ₹4.13 Cr | -₹69.44 Cr | -₹158.68 Cr | ₹33.4 Cr | ₹40.16 Cr |
| Net Profit | ₹183.64 Cr | ₹2,886.21 Cr | ₹65.49 Cr | ₹4.68 Cr | ₹180.19 Cr | ₹78.24 Cr | ₹111.7 Cr |
| Other Comprehensive Income | -₹56.69 Cr | -₹3.15 Cr | -₹12.8 Lakh | ₹3.62 Cr | -₹4.02 Cr | ₹23.93 Cr | -₹35.37 Cr |
| Total Comprehensive Income | ₹126.95 Cr | ₹2,883.06 Cr | ₹65.36 Cr | ₹8.3 Cr | ₹176.17 Cr | ₹102.17 Cr | ₹76.33 Cr |
| EBITDA (computed) | ₹408.11 Cr | ₹308.63 Cr | ₹327.58 Cr | ₹182.54 Cr | ₹200.12 Cr | ₹276.32 Cr | ₹310.2 Cr |
| Basic EPS | ₹19.92 | ₹6.43 | ₹7.20 | ₹0.52 | ₹20.08 | ₹8.73 | ₹12.47 |
| Diluted EPS | ₹19.92 | ₹6.43 | ₹7.19 | ₹0.52 | ₹20.07 | ₹8.72 | ₹12.47 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹5,395.72 Cr | ₹5,030.95 Cr | ₹5,837.78 Cr | ₹5,619.74 Cr |
| Non-current Assets | ₹3,022.13 Cr | ₹2,885.44 Cr | ₹3,421.93 Cr | ₹3,493.34 Cr |
| Current Assets | ₹2,373.59 Cr | ₹2,145.5 Cr | ₹2,415.86 Cr | ₹2,126.4 Cr |
| Property, Plant & Equipment | ₹634.2 Cr | ₹606.42 Cr | ₹507.87 Cr | ₹555.67 Cr |
| Inventories | ₹580.27 Cr | ₹431.71 Cr | ₹470.18 Cr | ₹490.76 Cr |
| Trade Receivables | ₹1,521.28 Cr | ₹1,452.93 Cr | ₹1,508.51 Cr | ₹1,307.78 Cr |
| Cash & Equivalents | ₹16.17 Cr | ₹6.33 Cr | ₹92.71 Cr | ₹82.11 Cr |
| Equity (Net Worth) | ₹3,283.52 Cr | ₹3,192.74 Cr | ₹3,561.12 Cr | ₹3,455.05 Cr |
| Equity Share Capital | ₹92.17 Cr | ₹92.16 Cr | ₹91.9 Cr | ₹90.3 Cr |
| Borrowings (Non-current) | ₹173.25 Cr | ₹127.37 Cr | ₹196.99 Cr | ₹284.74 Cr |
| Borrowings (Current) | ₹974.89 Cr | ₹1,028.88 Cr | ₹1,397.19 Cr | ₹1,064.46 Cr |
| Total Debt (computed) | ₹1,148.14 Cr | ₹1,156.25 Cr | ₹1,594.18 Cr | ₹1,349.2 Cr |
| Current Liabilities | ₹1,840.07 Cr | ₹1,629.61 Cr | ₹1,995.3 Cr | ₹1,796.83 Cr |
| Total Liabilities | ₹2,112.2 Cr | ₹1,838.21 Cr | ₹2,276.66 Cr | ₹2,164.69 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹277.85 Cr | ₹421.48 Cr | -₹35.76 Cr | ₹241.74 Cr | -₹282.69 Cr |
| Investing Cash Flow | -₹69.07 Cr | -₹137.59 Cr | -₹61.27 Cr | -₹182.58 Cr | ₹18.78 Cr |
| Financing Cash Flow | -₹198.93 Cr | -₹370.32 Cr | ₹107.62 Cr | ₹10.82 Cr | ₹250.73 Cr |
| Capital Expenditure | ₹168.57 Cr | ₹166.2 Cr | ₹67.29 Cr | ₹80.69 Cr | ₹68.17 Cr |
| Free Cash Flow (computed) | ₹109.27 Cr | ₹255.28 Cr | -₹103.05 Cr | ₹161.05 Cr | -₹350.86 Cr |
| Dividends Paid | ₹36.87 Cr | ₹22.99 Cr | ₹13.55 Cr | ₹0 | ₹22.43 Cr |
| Net Change in Cash | ₹9.84 Cr | -₹86.42 Cr | ₹10.6 Cr | ₹69.98 Cr | -₹13.18 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹605.74 Cr | ₹553.63 Cr | ₹522.15 Cr | ₹498.62 Cr | ₹555.96 Cr | ₹550.92 Cr | ₹609.96 Cr | ₹554.75 Cr | ₹617.63 Cr | ₹520.02 Cr | ₹540.29 Cr | ₹475.32 Cr |
| Other Income | ₹3.97 Cr | ₹103.24 Cr | ₹14.09 Cr | ₹1.76 Cr | ₹12.12 Cr | ₹2.43 Cr | ₹23.55 Cr | ₹11.83 Cr | ₹29.63 Cr | ₹8.69 Cr | ₹22.34 Cr | ₹11.65 Cr |
| Total Income | ₹609.71 Cr | ₹656.88 Cr | ₹536.24 Cr | ₹500.37 Cr | ₹568.08 Cr | ₹553.35 Cr | ₹633.5 Cr | ₹566.58 Cr | ₹647.27 Cr | ₹528.7 Cr | ₹562.63 Cr | ₹486.97 Cr |
| Cost of Materials Consumed | ₹297.46 Cr | ₹255.5 Cr | ₹255.66 Cr | ₹210.98 Cr | ₹268.29 Cr | ₹295.26 Cr | ₹301.91 Cr | ₹253.77 Cr | ₹266.45 Cr | ₹302.14 Cr | ₹288.94 Cr | ₹215.1 Cr |
| Purchases of Stock-in-Trade | ₹15.89 Cr | ₹17.75 Cr | ₹30.01 Cr | ₹15.75 Cr | ₹10.65 Cr | ₹32.27 Cr | ₹7.5 Cr | ₹12.21 Cr | ₹10.99 Cr | ₹6.6 Cr | ₹6.42 Cr | ₹5.21 Cr |
| Changes in Inventories | ₹10.9 Lakh | -₹90.3 Lakh | -₹3.65 Cr | ₹15.46 Cr | ₹3.3 Cr | -₹47.96 Cr | ₹6.14 Cr | ₹13.45 Cr | ₹34.09 Cr | -₹36.59 Cr | -₹2.43 Cr | ₹9.55 Cr |
| Employee Benefit Expense | ₹95.94 Cr | ₹95.14 Cr | ₹96.49 Cr | ₹94.04 Cr | ₹91.86 Cr | ₹93.8 Cr | ₹96.76 Cr | ₹94.87 Cr | ₹86.6 Cr | ₹85.66 Cr | ₹86.25 Cr | ₹76.7 Cr |
| Finance Costs | ₹26.66 Cr | ₹27.25 Cr | ₹29.41 Cr | ₹30.45 Cr | ₹29.36 Cr | ₹34.21 Cr | ₹50.15 Cr | ₹46.88 Cr | ₹46.77 Cr | ₹44.47 Cr | ₹40.07 Cr | ₹36.63 Cr |
| Depreciation & Amortisation | ₹25.19 Cr | ₹22.4 Cr | ₹21.51 Cr | ₹22.14 Cr | ₹22.37 Cr | ₹20.92 Cr | ₹21.98 Cr | ₹20.32 Cr | ₹20.81 Cr | ₹21.06 Cr | ₹21.34 Cr | ₹21.46 Cr |
| Other Expenses | ₹121.95 Cr | ₹104.95 Cr | ₹81.42 Cr | ₹95.16 Cr | ₹113.92 Cr | ₹103.45 Cr | ₹134.63 Cr | ₹119.41 Cr | ₹128.72 Cr | ₹96.55 Cr | ₹117.84 Cr | ₹113.19 Cr |
| Total Expenses | ₹583.2 Cr | ₹522.07 Cr | ₹510.86 Cr | ₹483.97 Cr | ₹539.76 Cr | ₹531.95 Cr | ₹619.06 Cr | ₹560.92 Cr | ₹594.41 Cr | ₹519.89 Cr | ₹558.43 Cr | ₹477.84 Cr |
| Profit Before Exceptional Items & Tax | ₹26.51 Cr | ₹134.8 Cr | ₹25.39 Cr | ₹16.4 Cr | ₹28.32 Cr | ₹21.39 Cr | ₹14.44 Cr | ₹5.66 Cr | ₹52.85 Cr | ₹8.81 Cr | ₹4.19 Cr | ₹9.13 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹1.7 Lakh | -₹1 Lakh | ₹0 | -₹7.4 Lakh | -₹5.29 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹26.51 Cr | ₹134.8 Cr | ₹25.39 Cr | ₹16.4 Cr | ₹28.32 Cr | ₹21.38 Cr | ₹14.43 Cr | ₹5.66 Cr | ₹52.78 Cr | ₹3.52 Cr | ₹4.19 Cr | ₹9.13 Cr |
| Total Tax Expense | ₹10.16 Cr | ₹12.91 Cr | -₹6.65 Cr | ₹3.06 Cr | ₹12.2 Cr | ₹6.44 Cr | -₹87.6 Lakh | ₹1.75 Cr | -₹88.6 Lakh | ₹97.8 Lakh | ₹2.91 Cr | ₹1.13 Cr |
| Net Profit | ₹16.35 Cr | ₹121.9 Cr | ₹32.04 Cr | ₹13.35 Cr | ₹16.13 Cr | ₹14.94 Cr | ₹15.31 Cr | ₹3.92 Cr | ₹53.66 Cr | ₹2.54 Cr | ₹1.28 Cr | ₹8 Cr |
| Other Comprehensive Income | -₹28.09 Cr | -₹2.87 Cr | -₹19.64 Cr | -₹6.09 Cr | -₹2.21 Cr | ₹6.42 Cr | -₹9.09 Cr | ₹1.74 Cr | -₹2.32 Cr | -₹6.91 Cr | ₹2.49 Cr | ₹6.61 Cr |
| Total Comprehensive Income | -₹11.74 Cr | ₹119.02 Cr | ₹12.4 Cr | ₹7.26 Cr | ₹13.92 Cr | ₹21.36 Cr | ₹6.22 Cr | ₹5.66 Cr | ₹51.35 Cr | -₹4.36 Cr | ₹3.77 Cr | ₹14.61 Cr |
| EBITDA (computed) | ₹78.36 Cr | ₹184.44 Cr | ₹76.32 Cr | ₹68.99 Cr | ₹80.05 Cr | ₹76.53 Cr | ₹86.58 Cr | ₹72.86 Cr | ₹120.43 Cr | ₹74.34 Cr | ₹65.61 Cr | ₹67.21 Cr |
| Basic EPS | ₹1.77 | ₹13.22 | ₹3.48 | ₹1.45 | ₹1.75 | ₹1.62 | ₹1.66 | ₹0.43 | ₹5.84 | ₹0.28 | ₹0.14 | ₹0.89 |
| Diluted EPS | ₹1.77 | ₹13.22 | ₹3.48 | ₹1.45 | ₹1.75 | ₹1.62 | ₹1.66 | ₹0.43 | ₹5.83 | ₹0.28 | ₹0.14 | ₹0.89 |
| Segment · FY 2024 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Bio-pharmaceutical business | ₹0 | ₹0 | - | - |
| Pharmaceutical business | ₹2,153.26 Cr | ₹237.55 Cr | - | - |
Shareholding Pattern of Strides Pharma Science Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 27.91%, foreign institutional investors hold 28.68%, domestic institutional investors hold 14.45%, retail and other public shareholders hold 28.95% of Strides Pharma Science Limited. The company had 86,616 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 27.91% | 27.86% | 27.86% | 28.30% | 28.30% | 26.82% |
| Public | 72.09% | 72.14% | 72.14% | 71.70% | 71.70% | 73.18% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 27.91% | 28.30% | 25.88% | 28.27% | 30.60% | 29.67% | 31.28% | 31.24% | 31.36% | 31.09% | 31.14% |
| Public | 72.09% | 71.70% | 74.12% | 71.73% | 69.40% | 70.33% | 68.73% | 68.76% | 68.64% | 68.91% | 68.86% |
| Promoter change (YoY, %pts) | -0.39 | +2.42 | -2.39 | -2.33 | +0.93 | -1.61 | +0.04 | -0.12 | +0.27 | -0.05 | - |
Board & Governance of Strides Pharma Science Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Strides Pharma Science Limited has 8 directors - 5 independent and 2 executive. The board is chaired by Arun Kumar Pillai.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Arun Kumar Pillai | Non-Executive - Non Independent Director · Chairperson | 1990-06-28 | 3 |
| Homi R Khusrokhan | Non-Executive - Independent Director | 2017-05-18 | 2 |
| Kausalya Santhanam | Non-Executive - Independent Director | 2019-12-11 | 2 |
| Ameet Pratheapsinh Hariani | Non-Executive - Independent Director | 2024-02-01 | 5 |
| Badree Komandur | Executive Director · CEO-MD | 2017-05-18 | 1 |
| Subir Chakraborty | Non-Executive - Independent Director | 2024-06-01 | 2 |
| Aditya Arun Kumar | Executive Director | 2024-06-01 | 1 |
| Mukta Arora | Non-Executive - Independent Director | 2025-02-01 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Homi R Khusrokhan (Chairperson), Kausalya Santhanam, Ameet Pratheapsinh Hariani, Subir Chakraborty, Mukta Arora |
| Nomination and remuneration committee | Ameet Pratheapsinh Hariani (Chairperson), Homi R Khusrokhan, Kausalya Santhanam, Subir Chakraborty, Mukta Arora, Arun Kumar Pillai |
| Stakeholders Relationship Committee | Kausalya Santhanam (Chairperson), Arun Kumar Pillai, Ameet Pratheapsinh Hariani, Subir Chakraborty |
| Risk Management Committee | Homi R Khusrokhan (Chairperson), Kausalya Santhanam, Badree Komandur, Ameet Pratheapsinh Hariani, Subir Chakraborty, Aditya Arun Kumar, Mukta Arora, Sormistha Gosh |
| Corporate Social Responsibility Committee | Kausalya Santhanam (Chairperson), Homi R Khusrokhan, Arun Kumar Pillai, Aditya Arun Kumar |
Group Structure of Strides Pharma Science Limited
Strides Pharma Science Limited has 3 subsidiary companies and 3 associated companies. This group structure data is as of FY 2023. The corporate group structure reflects Strides Pharma Science Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|
Showing major subsidiaries. Total: 3.
Charges & Borrowings of Strides Pharma Science Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Oct 2023 | Hdfc Bank Limited | ₹64.39 Lakh | Open |
| 19 Jul 2016 | Others | ₹1,879.62 Cr | Open |
| 27 Mar 2025 | Others | ₹100 Cr | Satisfied |
| 10 Feb 2025 | Karnataka Bank Ltd. | ₹100 Cr | Satisfied |
| 26 Sep 2024 | State Bank of India | ₹510 Cr | Satisfied |
Total charge records: 274 View all charges
Employees and EPFO Compliance at Strides Pharma Science Limited
Strides Pharma Science Limited has a workforce of 2,152 employees as of Nov 19, 2024.
Employee Count & EPFO Data of Strides Pharma Science Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Strides Pharma Science Limited
GSTIN & GST Filing Data of Strides Pharma Science Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Strides Pharma Science Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Strides Pharma Science Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Strides Pharma Science Limited
MSME Payment Delays by Strides Pharma Science Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Strides Pharma Science Limited
Subsidiaries & Group Companies of Strides Pharma Science Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Strides Pharma Science Limited with ownership details.
MCA Filings & Documents of Strides Pharma Science Limited
MCA Filings & Documents of Strides Pharma Science Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Strides Pharma Science Limited
Recent News on Strides Pharma Science Limited
Frequently Asked Questions about Strides Pharma Science Limited
Strides Pharma Science Limited is an active public limited company in the pharma sector based in Thane, Maharashtra, India. It was incorporated on 28 June 1990 (36+ years old) and is registered under CIN L24230MH1990PLC057062. Listed on BSE: 532531 and NSE: STAR. The company has 2,152 employees.
Strides Pharma Science Limited reported revenue of ₹4,624.06 Cr for FY 2025 (up 18.00% YoY).
The current directors of Strides Pharma Science Limited are:
- Homi Rustam Khusrokhan
- Badree Komandur
- Subir Chakraborty
- Ameet Pratapsinh Hariani
- Aditya Arun Kumar
- Mukta Malik Arora
- Kausalya Santhanam
- Manjula Ramamurthy
- Arun Kumar Pillai
- Vikesh Kumar
The primary industry of Strides Pharma Science Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Strides Pharma Science Limited is listed on both BSE (code: 532531) and NSE (symbol: STAR).
Strides Pharma Science Limited can be reached at the registered office: Cyber One Unit No. 902 Sector 30A, Plot No – 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703, or through the website strides.com.